Eloxx Pharmaceuticals (ELOX) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 61 157 sessions, October 22, 2025 to October 27, 2026
- Largest daily move
- +99900% close of March 18, 2026
- 1-year change
- +1212627.3% closing prices, October 22, 2025 to October 27, 2026
- 1-month change
- -11.2% closing prices, September 25, 2026 to October 27, 2026
Company Description
Eloxx Pharmaceuticals (NASDAQ: ELOX) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $53.5M.
ELOX has gained 1212627.3% over the past year. The last closing price was $13.34.
For FY2025, Eloxx Pharmaceuticals reported revenue of $0 with net income of -$6.0M and diluted earnings per share of -$5.34.
This page collects what Stock Titan holds for ELOX, including price data, latest news, SEC filings, financial highlights, upcoming events, and short interest trends.
Stock Performance
Eloxx Pharmaceuticals (ELOX) closed at $13.34 on October 27, 2026. Over the past 12 months, the price has gained 1212627.3%.
ELOX Metrics & Rankings
Price returns through October 27, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
Eloxx Pharmaceuticals has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 3 with negative movement. Key topics include clinical trial, management, earnings, offering. View all ELOX news →
SEC Filings
Eloxx Pharmaceuticals has filed 10 recent SEC filings, including 2 Form 8-K, 2 Form SCHEDULE 13G, 1 Form 3, 1 Form 4. The most recent filing was submitted on October 21, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all ELOX SEC filings →
Financial Highlights
operating income reached -$6.4M, and net income was -$6.0M. Diluted earnings per share stood at -$5.34. The company generated -$6.3M in operating cash flow. The current ratio was 0.31, measuring current assets divided by current liabilities.
Upcoming Events
ADPKD Phase 2 trial
Exaluren topline data
Topline data release
Phase 2 first dosing
Final readout
Topline results release
Eloxx Pharmaceuticals has 6 upcoming scheduled events. The next event, "ADPKD Phase 2 trial", is scheduled for January 1, 2027 (in 65 days). Investors can track these dates to stay informed about potential catalysts that may affect the ELOX stock price.
Short Interest History
Short interest in Eloxx Pharmaceuticals (ELOX) currently stands at 53.9 thousand shares, up 18.2% from the previous reporting period, representing 1.7% of the float. Since October 2025, short interest has increased by 2528.4%.
Days to Cover History
Days to cover for Eloxx Pharmaceuticals (ELOX) currently stands at 2.4 days, up 75.4% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since October 2025, the figure has increased by 142%. Across the settlements charted above, it has ranged from 1.0 to 1000.0 days.
ELOX Company Profile & Sector Positioning
Eloxx Pharmaceuticals (ELOX) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing ELOX often look at related companies in the same sector, including REGENERX BIOPHARMS INC (RGRX), NEXIMMUNE INC (NEXI), EFFECTOR THERAPUTCS INC (EFTR), GRITSTONE BIO INC (GRTSQ), and INNOVEREN SCIENTIFIC INC (IVRN). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ELOX's relative position within its industry.